About
Molbio Diagnostics is a point-of-care diagnostics company that develops and manufactures healthcare technologies for diagnosing infectious and non-communicable diseases. The company’s core business revolves around its proprietary 'Truenat' platform, a portable, battery-operated polymerase chain reaction (PCR) system designed for use in resource-limited settings. This platform provides rapid and accurate test results within approximately one hour. The company's primary source of revenue is the sale of its 'Truenat' devices and the recurring sale of compatible, disease-specific micro-PCR test kits. Molbio offers a wide range of tests for various infectious diseases, including tuberculosis, COVID-19, Hepatitis B and C, HIV, and HPV. Through its subsidiaries, the company also provides devices related to radiology and digital pathology.
IPO schedule
| Issue open date | 2026-08-10 |
| Issue close date | 2026-08-12 |
| UPI mandate deadline | 2026-08-12 (5 PM) |
| Allotment finalization | 2026-08-13 |
| Refund initiation | 2026-08-14 |
| Share credit | 2026-08-14 |
| Listing date | 2026-08-17 |
| Mandate end date | 2026-08-27 |
| Lock-in end date for anchor investors (50%) | 2026-09-11 |
| Lock-in end date for anchor investors (remaining) | 2026-11-10 |
Financials
| Financial Year Ended | March 2024 | March 2025 | March 2026 |
| Total Assets | 1221.06 | 1461.56 | 2148.42 |
| Revenue | 840.66 | 1027.94 | 1455.17 |
| Profit After Tax | 83.54 | 138.58 | 164.14 |
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 939.70 |
| Fresh Issue - Proceeds go to the company | 200 |
| Offer for sale - Proceeds go to the existing investors | 739.70 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| R&D facility, Centre of Excellence and office infrastructure | 105.5 (52.75%) |
| Plant, machinery and equipment for manufacturing units | 72.2 (36.10%) |
| General corporate purposes | 22.3 (11.15%) |
Strengths
- Proprietary TruNAT platform enables rapid, point-of-care molecular diagnostics.
- Strong footprint in government and public health procurement programs.
- Wide disease coverage including TB, COVID-19, HIV, hepatitis and HPV.
- In-house R&D supported by integrated manufacturing capabilities.
- Global presence with products deployed across multiple countries.
Risks
- Heavy dependence on government and international aid agency funding.
- High revenue concentration from tuberculosis-related test kits.
- A limited number of large customers contribute a significant share of revenues.
- Regulatory delays may impact the commercialisation of new diagnostic tests.
- Demand fluctuations are linked to public health policies and funding cycles.
Allotment Status for Molbio Diagnostics
To check your IPO allotment status:
- Visit the Kfin Technologies IPO Application Status page.
- Select the company name from the dropdown menu.
- Select and enter one of the following: PAN, Application Number, DP/Client ID, or Account Number/IFSC.
- Click Submit to view your allotment status.